Literature DB >> 678512

Highly active position eight analogues of somatostatin and separation of peptide diastereomers by partition chromatography.

C A Meyers, D H Coy, W Y Huang, A V Schally, T W Redding.   

Abstract

Six stereochemically pure analogues of somatostatin (SS), D- and L-5F-Trp8-SS, D- and L -6F-Trp8-SS, and D- and L-5Br-Trp8-SS, were synthesized and found to be more potent than somatostatin in suppressing the release of growth hormone from cultured rat pituitary cells. Two of the analogues, D-5F-Trp8- and D-5Br-Trp8-SS, were respectively 25 and 30 times more active than somatostatin in that assay. The analogues were prepared by solid phase synthesis of their corresponding diastereomeric mixtures, followed by their complete resolution by preparative partition chromatography. Reversed phase high pressure liquid chromatography (HPLC) was used to monitor the resolution and also to check the final purity of each peptide. Positive identification of each diastereoisomer was determined by amino acid analyses of their enzymatic digests, direct comparison with a known all-L standard in the case of the 5F-Trp8 analogues, and chromatographic separation of dansylated amino acids following enzymatic digestion of D- and L-5Br-Trp8-SS. The role of tryptophan in somatostatin is discussed and it is suggested that maintenance of physiological activity in somatostatin peptides, at least on the pituitary, is partially dependent upon the degree of resonance in the indole nucleus in position 8.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678512     DOI: 10.1021/bi00605a011

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Structure-activity relationships of somatostatin analogs in the rabbit ileum and the rat colon.

Authors:  L E Rosenthal; D J Yamashiro; J Rivier; W Vale; M Brown; K Dharmsathaphorn
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

2.  Synthesis and biological actions of prosomatostatin.

Authors:  C A Meyers; W A Murphy; T W Redding; D H Coy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

3.  The energetics of Na-dependent solute transport in isolated cells [proceedings].

Authors:  A A Eddy
Journal:  J Physiol       Date:  1978-12       Impact factor: 5.182

4.  Synthesis and biological activity of highly potent octapeptide analogs of somatostatin.

Authors:  R Z Cai; B Szoke; R Lu; D Fu; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.

Authors:  C A Meyers; D H Coy; W A Murphy; T W Redding; A Arimura; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

6.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Authors:  Renzo Cescato; Judith Erchegyi; Beatrice Waser; Véronique Piccand; Helmut R Maecke; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2008-06-11       Impact factor: 7.446

7.  Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.

Authors:  I Torres-Aleman; T W Redding; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

Review 8.  Current diagnosis and management of Zollinger-Ellison syndrome.

Authors:  D K Andersen
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

9.  Peptide aromatic interactions modulated by fluorinated residues: Synthesis, structure and biological activity of Somatostatin analogs containing 3-(3',5'difluorophenyl)-alanine.

Authors:  Pablo Martín-Gago; Álvaro Rol; Toni Todorovski; Eric Aragón; Pau Martin-Malpartida; Xavier Verdaguer; Mariona Vallès Miret; Jimena Fernández-Carneado; Berta Ponsati; Maria J Macias; Antoni Riera
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.